Needham Downgrades Verrica Pharmaceuticals (VRCA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
October 2, 2024 7:30 AM EDT- Company significantly reduces cost structure with a realigned sales, marketing and operational infrastructure
- Sales and marketing efforts to focus on pediatricians and expand access beyond dermatologists Â
WEST CHESTER, Pa., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica or the Company) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced a restructuring of its sales and operating teams to reduce costs and expand access to YCANTH® for the treatment of molluscum contagiosum.
These operational changes to... More
